NFC-1
MDGN-NFC1-22Q-101
Phase 1 small_molecule completed
Quick answer
NFC-1 for 22q11.2 Deletion Syndrome is a Phase 1 program (small_molecule) at Avalo Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Avalo Therapeutics
- Indication
- 22q11.2 Deletion Syndrome
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed